

# **Biomolecular recognition using aptamers**

Literature seminar #1

2024.12.19

M1 Ryo Okuma

# Contents

- Introduction
  - Aptamer Characteristics
  - Advantages and disadvantages of aptamers
  - Current applications of aptamers
  
- Development of new applications of aptamers
  - Ligand-directed catalysis
  - TDP-43 imaging in cell
  
- Perspective
  
- Summary

# Contents

## ■ Introduction


- **Aptamer Characteristics**
- **Advantages and disadvantages of aptamers**
- **Current applications of aptamers**

## ■ Development of new applications of aptamers

- Ligand-directed catalysis
- TDP-43 imaging in cell

## ■ Perspective






## ■ Summary



# Aptamers are a type of oligonucleotide therapies


## Aptamer

- single stranded DNA/RNA
- three-dimensional structure
- high specificity due to intermolecular forces

	Antisense oligonucleotides	siRNA	miRNA (mimic)	Aptamer	CpG oligonucleotides
Typical structure	Single-stranded DNA/RNA 	Double-stranded RNA 	Double-stranded RNA 	Single-stranded DNA/RNA 	Single-stranded DNA 
Mechanism of action	 mRNA degradation, Suppression of transcription, etc.      Inhibition of miRNA	 mRNA degradation	 mRNA degradation      Suppression of transcription	 Inhibition of protein function	 Stimulation of immune system
Characteristics	A variety of mechanisms exist e.g. mRNA degradation, splicing regulation, inhibiting miRNA.	Specific effect to mRNA with complementary sequences.	Single miRNA can regulate several mRNA transcripts.	High specificity due to three-dimensional structure-dependent effect.	Applying innate immune system to oligonucleotides via TLR9 which is considered as a side effect.
DDS/ miscellaneous	Chemically modified oligonucleotides are often used and DDS is not usually required.	Chemically modified oligonucleotides have recently been developed but DDS is generally required.	Generally DDS is required.	PEG modification is often used in order to extend blood circulation time.	Mixed with antigen as an adjuvant.

# SELEX : Systematic Evolution of Ligands by Exponential enrichment

## Schematic depiction of SELEX



- In general, aptamers are selected and obtained based on their binding affinity to target molecules using a method called SELEX.
- ✓ high affinity for the target ( $K_d = \text{nM} \sim \text{pM}$ )
- ✓ High binding specificity

# Aptamers have many advantages over antibodies.

	<b>aptamer</b>	<b>antibodies</b>
Molecular weight	Middle (~12-30 kDa)	Relatively big (~150-180 kDa)
Preparation method	Chemical method	Biological method
Generation time	Few hours to months	Several months(~ 6 months )
Cost	Lower	Higher
Allowed chemical modification	Various modifications	Limited modifications
Stability	Very stable	Sensitive to temperature and pH changes
Immunogenicity	Low	High

# Disadvantages of aptamers and solutions


## Disadvantages

- × Degradation by nuclease
- × prone to renal filtration (腎ろ過)
- × Low cell membrane permeability




## Solutions

- Chemical modifications (e.g. 2'-OH → -OMe, -F)
- Increase molecular weight by adding PEG



# Aptamers that control biomolecular reactions


## Macugen




- Macugen is the first therapeutic aptamer
- VEGF(血管内皮增殖因子) inhibitor

Tian, L.; *et al. Sci. China. Chem.* **2021**, 65 (3), 574–583.

## PD-L1 binding aptamer




## Aptamer-PROTAC



Zhang, T.; *et al. Nanotechnol.* **2021**, 33 (16), 162001–162001.  
 Feng, Y.; *et al. ACS Pharmacol. Transl. Sci.* **2024**, 7 (12), 3945-3954.


# Aptamers are useful as biosensors

## Electrochemical aptamer-based (E-AB) biosensor




- conformational change of the aptamer  
→ produce an electrical signal change

## Aptamer lateral flow assay (LFA)




- target molecules bind both the aptamer-conjugated gold NP detection agent and the aptamer capture agent  
→ turning the test band dark.

## Detection of cancer cells in whole blood




# Aptamer-based imaging methods are being developed

## mRNA imaging



- Molecules that fluoresce when bound to aptamers
- Aptamers can be expressed intracellularly

## Cell membrane protein imaging



Pietro Delcanale; et al. *Angew. Chem. Int. Ed.* **2020**, 59 (42), 18546–18555  
Yan, P.; et al. *Anal. Chem.* **2023**, 95 (37), 13762–13768

# Contents

## ■ Introduction


- Aptamer Characteristics
- Advantages and disadvantages of aptamers
- Current applications of aptamers

## ■ Development of new applications of aptamers

- **Ligand-directed catalysis**
- TDP-43 imaging in cell


## ■ Perspective

## ■ Summary






# Site-selective acylation of protein with aptamer-catalyst conjugates

## Schematic depiction



## Aptamer-tethered catalysts





TBA 1


TBA 2

# DMAP-aptamer modified Lys residues site-selectively

protocol




TBA<sup>3</sup>-DMAP




acylation yield : 27 %

TBA<sup>12</sup>-DMAP






acylation yield : 49 %



- Aptamer-DMAP modification was performed in a site-selective manner
- Modification was performed on Lys proximal to the respective DMAP

# DMAP-aptamer specifically modified thrombin

protocol







- Only fluorescently labelled thrombin was observed and none of the other proteins was modified


→ DMAP-aptamer conjugates specifically modify its target protein

# Different aptamer-catalysts modified different sides of thrombin

protocol



Acylation yield : > 90 %




Acylation yield : 20-27 %

- TBA1-diPyOx and TBA2-diPyOx bind to the different sides of thrombin
- TBA-diPyOx modified thrombin at residues positioned in close proximity to the respective positions of the catalyst

# Activity control of TBA-catalyst construct




## Schematic depiction



- OFF strand : hybridize with TBA-catalyst  
→ form a catalytically inactive dsDNA duplex
- ON strand : complementary to the OFF strand  
→ bind to OFF strand and the TBA is reformed



- Upon addition of the OFF-strand, the system turned to its OFF state as no protein modification was detected.
- After removing the OFF-strand by addition of the ON strand, the modification of thrombin is again efficient.  
→ this switch successfully control the activity of TBA-catalysts

## protocol



# Short summary

- This research shows the first DNA-based catalyst for the **site-selective modification** of a specific protein **using its affinity for an aptamer**.
- The activity of our DNA-based catalysts **could be repeatedly regulated** by an external stimulus.



# Contents

## ■ Introduction


- Aptamer Characteristics
- Advantages and disadvantages of aptamers
- Current applications of aptamers

## ■ Development of new applications of aptamers

- Ligand-directed catalysis
- TDP-43 imaging in cell


## ■ Perspective

## ■ Summary




# TDP-43

## The domain organization of TDP-43



- In vitro experiments have been performed using the RRM1-2 domain


## The localization of TDP-43



- The majority of TDP-43 is localized in the nucleus in soluble forms
- A portion of TDP-43 exists as a monomer in the cytoplasm
- Disturbance in the equilibrium between the oligomeric and monomeric TDP-43 in the cytoplasm may result in aggregates




# Aptamers that bind to TDP-43 were designed in silico

## Interaction between RNA and TDP-43



**e**





	Sequence	TDP-43	RRM1	RRM2	RRM1-2
<b>Apt-1</b>	CGGUGUUGCU	0.99	0.90	0.52	0.93
<b>Apt-2</b>	GUGGUCCCCG	0.98	0.85	0.55	0.90
<b>Apt-3</b>	CGCUGUGGUC	0.94	0.90	0.45	0.86
<b>Apt-4</b>	GGGUGUGGGC	0.88	0.83	0.40	0.75
<b>Apt-5</b>	CGAGGCCGGG	0.82	0.81	0.40	0.78
<b>Apt-6</b>	GCGGGGCCCG	0.75	0.81	0.61	0.75



- *catRAPID* = protein-RNA interactions prediction
- iCLIP = protein-RNA interactions database
- *catRAPID* and iCLIP are corresponding → good prediction
- Protein Fitness Score  
Score ~1 = strong interaction for TDP-43 compared to other proteins
- RNA Fitness Score  
Score ~1 = strong interaction for TDP-43

# Aptamers that bind to TDP-43 were designed in silico

## Interaction between RNA and TDP-43




**e**

	Sequence	TDP-43	RRM1	RRM2	RRM1-2
<b>Apt-1</b>	CGGUGUUGCU	0.99	0.90	0.52	0.93
<b>Apt-2</b>	GUGGUCCCCG	0.98	0.85	0.55	0.90
<b>Apt-3</b>	CGCUGUGGUC	0.94	0.90	0.45	0.86
<b>Apt-4</b>	GGGGUGGGGC	0.88	0.83	0.40	0.75
<b>Apt-5</b>	CGAGGCCGGG	0.82	0.81	0.40	0.78
<b>Apt-6</b>	GCGGGGCCCG	0.75	0.81	0.61	0.75

- *catRAPID* = protein-RNA interactions prediction
- iCLIP = protein-RNA interactions database
- *catRAPID* and iCLIP are corresponding  
→ good prediction
- RNA Fitness Score  
Score ~1 = strong interaction for TDP-43
- Protein Fitness Score  
Score ~1 = strong interaction for TDP-43  
compared to other proteins

# The aptamers bound to RRM1-2 in vitro

## Binding affinity of Apt-1 and nApt-1 for RRM1-2




- nApt-1 : the reverse complementary RNA of Apt-1 (negative control)
- Apt-1 has the strong affinity with a  $K_d = 0.1 \mu\text{M}$  whereas nApt-1 :  $K_d = 1.5 \mu\text{M}$

**Table 1** Binding affinities of the RNA aptamers for RRM1 and RRM1-2.

	$K_d$ screening (μM)	
	RRM1	RRM1-2
Apt-1	0.58 ± 0.01	0.10 ± 0.01
Apt-2	1.44 ± 0.40	0.75 ± 0.15
Apt-3	0.90 ± 0.20	0.65 ± 0.12
Apt-4	0.90 ± 0.35	1.30 ± 0.45
Apt-5	1.65 ± 0.30	1.50 ± 0.30
Apt-6	2.50 ± 0.65	1.60 ± 0.40


$K_d$  values of candidate RNA aptamers interactions with the isolated RRM1 of TDP-43 (second column) and RRM1-2 (third column); mean ± S.D.;  $n = 3$ ).



- The experimental  $K_d$  values correlate with the predicted Protein Fitness scores  
→ validation of the computational design of RNA aptamers


# DNA-PAINT (DNA-Point Accumulation for Imaging in Nanoscale Topography)

## RNA-fluorescent molecules



- labeled RNA aptamers transiently bind to TDP-43
- the fluorescent molecule emits signal only when it binds

## Super-resolution imaging (SR imaging)



Record the location of many bright spots


↓  
Calculate the center of bright spots

↓  
Integrate them to build up a SR image


Schnitzbauer, J.; *et al. Nat. Protoc.* **2017**, 12 (6), 1198–1228.  
van. <https://doi.org/10.13140/RG.2.2.23165.13285>.

# SR Imaging of RRM1-2 aggregates with Apt-1


## AD-PAINT




## Protocol





## PAINT imaging



## e RRM1-2



## PAINT imaging





- Apt-1 could build up the SR image of RRM1-2

- The number of aggregates detected with Apt-1 was significantly higher than with nApt-1

# Following the aggregation of RRM1-2 using Apt-1 and SAVE imaging


## PAINT w/ Apt-1 vs SAVE w/ ThT

### Protocol




PAINT imaging  
SAVE imaging

### Detected using Apt-1




### Detected using ThT



## Following the aggregation of RRM1-2

**a**




- Apt-1 visualized RRM1-2 aggregates with SR microscopy as they formed over 72 h
- Enabling their size to be accurately measured

- The number of aggregates detected with Apt-1 was significantly higher than with ThT
- Only 6 % of the aggregates detected with Apt-1 was ThT-active  
→ Apt-1 could identify less mature oligomers

# Apt-1 does not bind to A $\beta$ or $\alpha$ -synuclein



## Binding affinity of Apt-1 and nApt-1 for A $\beta$ 42 or $\alpha$ -synuclein






- No binding was observed at 10  $\mu$ M for A $\beta$ 42 and  $\alpha$ -synuclein in their soluble forms
- Aggregates composed of both proteins were not detected

→ Apt-1 has a specificity toward TDP-43

## PAINT imaging of A $\beta$ 42 or $\alpha$ -synuclein



# Confocal microscopy analysis of TDP-43 and Apt-1 in live mammalian cells



- Apt-1 (red) co-localizes with TDP-43 (green) in cells
- These images suggest an interaction between soluble/mislocalized and aggregated TDP-43 and Apt-1
- nApt-1 (negative control) does not co-localize with TDP-43 in cells

↓  
Aptamers designed with catRAPID could be employed as probes for the visualization and identification of TDP-43

# Short summary


- This study shows a computational pipeline for **de novo design of RNA aptamers in silico**
- The ability of **catRAPID overcomes the limitations of SELEX**  
SELEX : need for libraries/reagents, a timeframe of **several months** and associated costs  
catRAPID : **between 2 and 7 days** depending on the molecule length
- Apt-1 could **visualize RRM1-2 aggregates with SR microscopy** as they formed over 72 h.  
--at the nanometer scale, enabling their sizes to be accurately measured.
- Imaging TDP-43 condensates **in the cell**.  
GFP often interferes with the condensation process.

## limitation


- this computational approach **does not include a pipeline to predict the effect of specific chemical modifications** to enhance RNA stability or avidity towards its target.
- Apt-1 is short, consisting of 10 base pairs, and does not form a three-dimensional structure  
This enabled intracellular imaging.  
← Because TDP-43 is an RNA-binding protein, it was able to bind with a short base-paired aptamer.  
This may be difficult for other proteins.

# Perspectives

## Engineered aptamers for molecular imaging



## Wearable microneedle-based electrochemical aptamer biosensing



Lin, B.; *et al. Chem. Sci.* **2023**, *14* (48), 14039–14061.

Lin, S.; *et al. Sci. Adv.* **2022**, *8* (38).